Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded

Will Seek EUA Shortly

Executive Summary

Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut. 

You may also be interested in...



Has UK Got Vaccine Strategy Right Again With Choice For Under 30s?

The UK has announced a ‘course correction’ on its vaccination program, and looks to have maintained public confidence so far – unfortunately the same cannot be said for EU countries

Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible

The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.

Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible

The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel